Nov 13, 2019 · In the current study, we examined soluble C5b-9 (sC5b9), the terminal complement complex, as a potential biomarker for the development of TMA among patients with active GVHD.

The Terminal Complement Complex (TCC, sC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway.

Laboratory tests measure the amount of soluble C5b-9 (sC5b-9) complex. The formation of C5b-9 and sC5b-9 is a consequence of activation of the complement system by either the classical, lectin, or alternative pathways.

MAC is composed of a complex of four complement proteins (C5b, C6, C7, and C8) that bind to the outer surface of the plasma membrane, and many copies of a fifth protein (C9) that hook up to one another, forming a ring in the membrane. C6-C9 all contain a common MACPF domain. [6] .

Oct 21, 2024 · Plasma SC5b-9 levels may be used to monitor the efficacy of complement inhibitor drugs, as elevated levels suggest insufficient complement blockage to effectively prevent the formation of the terminal attack complex.

Elevations in soluble Complement 5b-9 (sC5b-9) have been associated with increased activation of the alternative complement pathway. Increased complement activation may be seen with aHUS and other TMAs, and may be a sensitive early predictor of the development of transplant associated TMA.

Oct 28, 2014 · For the clinician, the value of sC5b-9 as a biomarker of aHUS disease activity remains unresolved. A collaborative study is needed in which sC5b-9 is measured in a large aHUS cohort in different disease phases by different laboratories.

We present a pilot study which aims to assess whether plasma soluble C5b-9 (sC5b-9) correlates with terminal complement complex (TCC) staining in kidney tissue. The secondary aim was to assess the utility of plasma sC5b-9 as part of routine workup in …

Noris et al2 reported that sC5b-9 is unsuitable as a biomarker of complement activation in aHUS because they found: (1) sC5b-9 levels were elevated in only 10 of 19 patients in the acute phase of disease, (2) 23 of 36 patients in remission continued to have elevated sC5b-9 levels, and (3) sC5b-9 levels did not change in 8 patients receiving ...

Laboratory tests measure the amount of soluble C5b-9 (sC5b-9) complex. The formation of C5b-9 and sC5b-9 is a consequence of activation of the complement system by either the classical, lectin, or alternative pathways.